Dishman Carbogen Amcis Ltd. witnessed a 5% jump in its share price after announcing a significant regulatory milestone. Its wholly owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has secured a Drug Manufacturing License from the National Medical Products Administration (NMPA) of China. At 10:36 AM, the shares were trading 4.60% higher at Rs 196.51.
The license, officially granted on April 8, 2025, allows the Shanghai-based facility to commence manufacturing operations in compliance with Chinese pharmaceutical regulations. This marks a key step in the company’s expansion strategy within Asia’s rapidly growing healthcare market.
In an exchange filing, Dishman Carbogen Amcis stated, “We are pleased to inform you that yesterday the Company’s wholly owned subsidiary namely CARBOGEN AMCIS (Shanghai) Co. Ltd., has received Drug Manufacturing License from the National Medical Product Administration (NMPA) for its Shanghai, China.”
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
